

Image copyright  
Dennis Kunkel Microscopy, Inc.

14<sup>TH</sup>

# SPORE

INVESTIGATORS' WORKSHOP

PROGRAM BOOK

BALTIMORE MARRIOTT WATERFRONT  
JULY 16-19, 2006

National Cancer Institute

U.S. DEPARTMENT  
OF HEALTH AND  
HUMAN SERVICES

National Institutes  
of Health



## Sunday, July 16

7:00 a.m. - 7:00 p.m.

**Registration**

*Grand Registration Desk*

Various Times

**Industry Learning Centers**

*See Agenda*

10:00 a.m. - 12 noon

**Prostate SPOREs National  
Biospecimen Network Pilot/  
Inter-Prostate Biomarkers Study**

*Waterview Ballroom*

12 noon - 1:00 p.m.

**Mentor/New Advocate Introductions**

*James*

1:00 p.m. - 8:00 p.m.

**Poster Setup**

*Harborside Ballroom*

1:00 p.m. - 2:30 p.m.

**caBIG™ Tissue Bank and  
Pathology Tools**

*Waterview Ballroom*

1:00 p.m. - 3:00 p.m.

**Lung Cancer Proteomics Meeting**

*Laurel A*

**Patient Advocates' Welcome Session**

*Laurel B-D*

1:00 p.m. - 3:00 p.m.

**NCI/SPORE Administrators' Meeting**

*Dover A-C*

3:00 p.m. - 6:00 p.m.

**Plenary Session**

*Grand Ballroom*

6:00 p.m. - 8:00 p.m.

**Welcome Reception**

*Grand Ballroom*

6:30 p.m. - 7:00 p.m.

**SPORE Program and Review Q&A**

*Grand Ballroom*

8:00 p.m. - 10:00 p.m.

**Skin SPOREs Meet & Greet (closed)**

*Laurel A & B*

## Monday, July 17

7:00 a.m. - 7:00 p.m.

**Registration**

*Grand Registration Desk*

Various Times

**Industry Learning Centers**

*See Agenda*

7:00 a.m. - 8:00 a.m.

**Early Morning Break**

*Various Locations*

**Inter-Prostate Biomarkers Study**

*Boardroom*

8:00 a.m. - 6:00 p.m.

**Poster Session**

*Harborside Ballroom*

8:00 a.m. - 12 noon

**Organ Site Breakout Session I**

- Bladder
- Breast
- Gastrointestinal/Pancreas
- Kidney
- Lung
- Ovarian/Gynecologic

*Salon I*

*Salon V*

*Salons III & IV*

*Salon II*

*Salon VI*

*Salons IX & X*

12 noon - 2:00 p.m.  
**SPORE Directors' and Patient Advocates' Working Luncheon (invitation only)** Waterview Ballroom

12 noon - 2:00 p.m.  
**Lunch on Your Own**

2:00 p.m. - 6:00 p.m.  
**Organ Site Breakout Session I**

- Brain *Salons IX & X*
- Head/Neck and Cervical *Salons III & IV*
- Hematological Malignancies *Salon VIII*
- Prostate *Salon V*
- Skin *Salons I & II*

6:00 p.m. - 9:00 p.m.  
**Meet-the-Author Poster Session and Dinner Buffet** Harborside Ballroom

## Tuesday, July 18

7:00 a.m. - 7:00 p.m.  
**Registration** Grand Registration Desk

Various Times  
**Industry Learning Centers** See Agenda

7:00 a.m. - 8:00 a.m.  
**Early Morning Break** Various Locations  
**Prostate SPOREs Directors' Meeting (invitation only)** Boardroom

8:00 a.m. - 6:00 p.m.  
**Poster Session** Harborside Ballroom

8:00 a.m. - 10:00 a.m.  
**Intellectual Property Management: Technology Transfer** Salon V  
**DHHS Cross-cutting Initiatives I**  
• FDA Critical Paths *Salons I-IV*  
• Image-Guided Serial Tissue Acquisition *Salon VI*

10:15 a.m. - 12:15 p.m.  
**Mini-symposia**  
• Cancer and Inflammation *Dover A-C*  
• Small Molecules in Cancer Therapy *Salon V*  
• Tumor Cells and Lineage Dependencies *Salons I-IV*  
• Steroid Hormone Receptors *Salon VI*  
• Oxidative Stress *Salons VII-X*

11:30 a.m. - 2:30 p.m.  
**Executive Luncheon (closed meeting)** Waterview Ballroom

12:15 p.m. - 2:15 p.m.  
**Clinical Trials and SPORE Patient Advocates' Luncheon (invitation only)** Laurel A-D

12:15 p.m. - 2:30 p.m.  
**Lunch on Your Own**

1:00 p.m. - 2:30 p.m.  
**Image-Guided Serial Tissue Acquisition: Technical Aspects Working Luncheon (bring your own lunch)** Dover A-C

2:30 p.m. - 5:30 p.m.

**Working Groups**  
• EGFR/HER2 Neu Targeted Therapies *Salons I-IV*  
• Methods in Validation of Biomarkers *Salon V*  
• Imaging: Correlation With Biomarkers in Translational Research and Therapy *Salon VI*  
• Clinical Trial Design in Translational Research *Salons VII-X*

5:45 p.m. - 7:45 p.m.

**FDA Regulatory Issues** *Salons I-IV*

**DHHS Cross-cutting Initiatives II**  
• Nanotechnology, Proteomics, and Genomics *Salon V*  
• NIH Roadmap Initiative *Salon VI*

6:00 p.m.

**Poster Take-down** Harborside Ballroom

7:45 p.m. - 9:45 p.m.

**Prostate SPOREs Clinical Trials Working Group** Boardroom

**Barrett's Esophagus and Esophageal Adenocarcinoma** Kent B

**I-SPY Trial: Investigators' Meeting** Laurel A & B

## Wednesday, July 19

7:00 a.m. - 12 noon  
**Registration** Grand Registration Desk

7:00 a.m. - 8:00 a.m.  
**Early Morning Break** Various Locations

8:00 a.m. - 10:00 a.m.  
**Concurrent Plenary Sessions**  
• Development of Biotechnologies in Cancer Research *Salons I-IV*  
• Molecular Monitoring of Risk and Recurrence *Salon V*  
• Development of Therapeutic Agents *Salon VI*  
• Human Therapeutic Interventions With Laboratory Correlates *Salons VII-X*

10:00 a.m. - 12 noon  
**Bladder SPORE Breakout Session II** Essex A-C

**Brain SPOREs Breakout Session II** Laurel C & D

**Breast SPOREs Breakout Session II** Harborside B

**Hematological Malignancies SPOREs Breakout Session II** Laurel A & B

**Prostate SPOREs Breakout Session II** Harborside A

**Lung Pathologists' Meeting** Dover A & B

12 noon

**Workshop Adjournment**

12 noon - 2:00 p.m.

**Advocate Wrap-up Session** James

## Internet and Speaker Ready Rooms

12 noon - 7:00 p.m.

Sunday

7:00 a.m. - 7:00 p.m.

Monday - Tuesday

7:00 a.m. - 12 noon

Wednesday

Internet Room - Atlantic

Speaker Ready Room - Bristol

At its core, this meeting is about science. It is about how to bring together multiple areas of expertise; it is about how to expedite the transition to application of new knowledge.

The National Cancer Institute relies on a cadre of committed scientists like you, who come together at workshops like this one to share their knowledge and insights with colleagues and to help us create a vision for better, stronger programs and, therefore, a better NCI.

The agenda for the 14th SPORE Investigators' Workshop explores innovative approaches that better allow researchers to advance basic discoveries into clinical applications, by predicting and preventing the mechanisms of carcinogenesis and by controlling the rates and methods of the disease's progression.

Last year's workshop was the first to include industry representatives, who discussed their research programs alongside SPORE investigators. Industry members are coming in greater numbers this year, expanding their participation to include the new Industry Learning Centers: forums designed for the robust exchange of ideas and for scientific interactions on areas from new therapeutic drugs to the potential development of biomarkers into commercial products that have the potential to impact clinical management of cancer patients.

This year's SPORE Investigators' Workshop also features the return of the Concurrent Plenary Sessions, which will highlight the most groundbreaking translational research efforts of the SPORE Program. Likewise, poster-viewing opportunities and Meet-the-Author sessions will help facilitate productive one-on-one dialogue.

Also new this year are mini-symposia and working group sessions, as well as a number of special sessions designed to address specific areas like intellectual property management, technology transfer, and FDA regulations.

The SPORE Workshop is an opportunity. It is a chance to strengthen existing collaborations, develop new collaborations, and share ideas about translational cancer research and about meeting the challenge of making a real difference for our patients with cancer—and their loved ones.

I welcome all of you to the 14th SPORE Investigators' Workshop and sincerely thank you for your dedication and service to NCI.

With admiration,



John E. Niederhuber, M.D.



**Industry Learning Centers**

*Industry Learning Centers provide industry representatives with an opportunity to exchange ideas and promote scientific interactions and collaborations among SPORE investigators, participants, and NCI.*

*Industry Learning Centers will close on Sunday, July 16, from 3 to 6 p.m. for the Opening Plenary Session.*

**Sunday, July 16****Asuragen, Inc.**

Essex A

miRNAs and mRNAs in biofluids and clinically derived tissues provide patient-specific information that can be used for the diagnosis of disease and prediction of therapeutic response. Asuragen, Inc., a molecular diagnostic spin-out of Ambion, Inc., has developed a suite of technologies and associated know-how to enable the discovery and validation of diagnostic RNA biomarkers and to create, manufacture, and launch assays that can be used to evaluate patient samples.



*Onsite Contact: Cindy Walker Peach, 512-567-8171*

**Pharmion Corporation**

Falkland

Learn about Pharmion's epigenetic therapies for cancer and discuss opportunities for collaboration on laboratory and clinical trials.



*Onsite Contact: Andrew Allen, 510-610-8684*

**Monday, July 17****Affymetrix, Inc.**

Kent B

Come learn about clinical applications of microarray signatures as disease classifiers.



*Onsite Contact: Scott Fogerty, 610-269-8538*

**AstraZeneca**

Laurel A

AstraZeneca representatives will be available to begin a dialogue with NCI and SPORE experts who may have mutual interest in our pipeline development portfolio. We seek to identify trends in external translational science and leaders doing the work.



*Onsite Contact: Gregory Curt, 301-792-2804*

**Asuragen, Inc.**

See Sunday, July 16, listing.

**Bristol-Myers Squibb****Galena**

BMS Oncology is developing a broad pipeline of anticancer agents, including kinase inhibitors, cytotoxics, and immunotherapies. Collaborations are encouraged between SPORE investigators and BMS scientists.



*Onsite Contact: Lewis Strauss, 203-430-0407*

**Cerus Corporation****Laurel C**

Representatives of the Cerus research and clinical teams will be available to discuss current cancer immunotherapy projects. These include the clinical investigation of live, attenuated listeria monocytogenes for patients with carcinomas and hepatic metastases, and the research and development program using recombinant listeria to elicit cellular immunity specific for mesothelin, a tumor antigen that is overexpressed in pancreas and ovarian carcinomas and mesotheliomas.



*Onsite Contact: Joseph Eiden, 510-773-0179*

**Dendreon Corporation****Essex B**

Come learn about our lead product candidate, sipuleucel-T. This investigational active cellular immunotherapy for the treatment of prostate cancer is in late-stage Phase III clinical development to evaluate its safety and potential effectiveness in advanced prostate cancer.



*Onsite Contact: Mike Casarella, 206-617-2936*

**Gene Express, Inc.****Laurel D**

The implementation of personalized medicine is contingent on standardization of genomic data and quality control in molecular diagnostics. Learn about StaRT-PCR™ and how it meets all of the performance characteristics defined by the FDA and CLIA as necessary for clinical diagnostics and new drug development.



*Onsite Contact: Colette Saccomanno, 201-893-2707*

**MedImmune, Inc.****Laurel B**

Meet representatives from MedImmune's preclinical and clinical teams to learn more about the biotechnology company's oncology programs. In particular, MedImmune researchers will highlight information about the potential role of a new molecular target, EphA2, and its overexpression in human cancers.



*Onsite Contact: Ron Lieberman, 301-404-7411*

**National Cancer Institute  
Center for Bioinformatics**

*Kent A*

caBIG™ Tissue Bank and Pathology Tools –  
Learn about NCI's software tools for  
biobanking and pathology.



*Onsite Contacts: Leslie Derr, 301-402-5792, and  
Ian Fore, 301-496-3355*

**Pharmion Corporation**

See Sunday, July 16, listing.

**Studylog Systems, Inc.**

*Heron*

Studylog will present a proposal to make  
in vivo cancer research more efficient and  
collaborative with an online in vivo study  
data repository.



*Onsite Contact: Eric Ibsen, 650-219-4055*

---

**Tuesday, July 18**

**Asuragen, Inc.**

See Sunday, July 16, listing.

**Bristol-Myers Squibb**

See Monday, July 17, listing.

**Dendreon Corporation**

See Monday, July 17, listing.

**Pharmion Corporation**

See Sunday, July 16, listing.

---

**Wednesday, July 19**

**Bristol-Myers Squibb**

See Monday, July 17, listing.

**14th SPORE Investigators' Workshop**

*The primary goal of the Workshop is to advance translational cancer research by expanding collaborations between SPORE investigators, NCI networks, industry, special guests, patient advocates, and NCI and NIH staff. This SPORE Workshop is the culmination of efforts of both basic and applied research scientists to share data, assess research strategies, identify new research opportunities, and establish priorities for research that are most likely to reduce cancer incidence and mortality and to increase survival.*

**Registration**

7:00 a.m. - 7:00 p.m.

Grand Registration Desk

**Industry Learning Centers**

See pages 3-5 for times and locations.

**Prostate SPOREs National Biospecimen Network Pilot/Inter-Prostate Biomarkers Study**

10:00 a.m. - 12 noon

Waterview Ballroom

**Mentor/New Advocate Introductions**

12 noon - 1:00 p.m.

James

**Internet Room**

12 noon - 7:00 p.m.

Atlantic

**Speaker Ready Room**

12 noon - 7:00 p.m.

Bristol

**Poster Setup**

1:00 p.m. - 8:00 p.m.

Harborside Ballroom



**caBIG™ Tissue Bank and Pathology Tools**

1:00 p.m. - 2:30 p.m.

Waterview Ballroom

**Lung Cancer Proteomics Meeting**

1:00 p.m. - 3:00 p.m.

Laurel A

**Patient Advocates' Welcome Session**

1:00 p.m. - 3:00 p.m.

Laurel B-D

**NCI/SPORE Administrators' Meeting**

1:00 p.m. - 3:00 p.m.

Dover A-C

*Moderator: Ivan Ding, National Cancer Institute*

1:00 p.m. **Icebreaker**  
To help get acquainted and learn to network

1:30 p.m. **Organ Systems Branch (OSB) Presentation**  
Program Director's Role  
SPORE Program Updates  
*Ivan Ding, National Cancer Institute*

1:50 p.m. **Interfacing With the Organ Systems Branch**  
Discussion on travel, SPORE public Web site, OSB requests for information and timeline, Special Population Tracking, and winter meeting logistics, and planning and updates for the SPORE Workshop  
*Sarah Fabian, Katherine Sachs, National Cancer Institute*

2:05 p.m. **SPORE Special Activities**  
Discussion on the SPORE Relational Database, SPORE Report publication and Supplements  
*Teri Brown, National Cancer Institute*

2:20 p.m. **SPORE Q&A Breakout Session: Grants Management, Review, and Program or *Everything You Wanted to Ask About the NCI***  
Discussion with principal players in Grants Management, Review, and Program

Sunday, July 16

## Plenary Session

**3:00 p.m. - 6:00 p.m.**

**Grand Ballroom**

This session is designed for the NCI leadership, SPORE investigators, and guests to share new information, highlights, opportunities, and scientific dialogue. During this opening session, NCI will present the SPORE Leadership Award and Outstanding SPORE Investigator Award. The Keynote Speakers, Kenneth Anderson and Edward Harlow, will culminate this session and launch the 14th SPORE Investigators' Workshop.

- 3:00 p.m.    **Opening Remarks and Overview of the SPORE Workshop**  
*Jorge Gomez, National Cancer Institute*
- 3:15 p.m.    **NCI's Commitment to the Progression of Translational Cancer Research**  
*Ernest Hawk, National Cancer Institute*
- 3:45 p.m.    **Oncogenomics To Target the Tumor Cell in Its Microenvironment**  
*Keynote Speaker: Kenneth Anderson, Dana-Farber Cancer Institute*
- 4:15 p.m.    **Outstanding Leadership and Investigator Awards**
- 4:45 p.m.    **Break**
- 5:00 p.m.    **The cancer Biomedical Informatics Grid (caBIG): Enabling the Patient-centric Molecular Medicine Revolution**  
*Kenneth Buetow, National Cancer Institute*
- 5:15 p.m.    **Functional Screens To Identify Physiological Differences Between Human Cell Lines**  
*Keynote Speaker: Edward Harlow, Harvard Medical School*
- 5:45 p.m.    **Peer Review of SPORE Applications**  
*Olivia Bartlett, National Cancer Institute*

## Welcome Reception

**6:00 p.m. - 8:00 p.m.**

**Grand Ballroom**

## SPORE Program and Review Q&A

**6:30 p.m. - 7:00 p.m.**

**Grand Ballroom**

## Skin SPOREs Meet & Greet (*closed*)

**8:00 p.m. - 10:00 p.m.**

**Laurel A & B**

---

**Internet Room**

---

**7:00 a.m. - 7:00 p.m.****Atlantic**

---

**Speaker Ready Room**

---

**7:00 a.m. - 7:00 p.m.****Bristol**

---

**Registration**

---

**7:00 a.m. - 7:00 p.m.****Grand Registration Desk**

---

**Industry Learning Centers**

---

**See pages 3-5 for times and locations.**

---

**Early Morning Break**

---

**7:00 a.m. - 8:00 a.m.****Various Locations**

---

**Inter-Prostate Biomarkers Study**

---

**7:00 a.m. - 8:00 a.m.****Boardroom**

---

**Poster Session**

---

**8:00 a.m. - 6:00 p.m.****Harborside Ballroom**

This session will offer investigators and industry the opportunity to present and share exciting research projects in an interactive forum. One-on-one interactions, networking, and discussions are highly encouraged in order to facilitate partnerships and collaborations.

---

**Organ Site Breakout Session I**

---

**8:00 a.m. - 12 noon**

These breakout sessions allow organ site programs to discuss (1) the most important recent scientific advancements, (2) opportunities and technologies that can be used to advance the field, (3) collaborations with other SPORE or NCI programs and networks, (4) infrastructures needed to support Inter-SPORE collaborations, and (5) proposed focused activities for upcoming fall or winter meetings.

**Bladder****Salon I**

- Chair: Colin Dinney, University of Texas M.D. Anderson Cancer Center*
- 8:00 a.m. **Update on the International Bladder Tumor Marker Study**  
*Frederic Waldman, University of California, San Francisco*
- 8:20 a.m. **Discussion**
- 8:30 a.m. **Genetic Predisposition to Bladder Cancer: From Risk to Clinical Outcome**  
*Xifeng Wu, University of Texas M.D. Anderson Cancer Center*
- 8:50 a.m. **Discussion**
- 9:00 a.m. **Cripto Expression by Bladder Cancer**  
*Liana Adam, University of Texas M.D. Anderson Cancer Center*
- 9:20 a.m. **Discussion**
- 9:30 a.m. **Break**
- 9:45 a.m. **Neoadjuvant Therapy for Bladder Cancer—A Platform for Translational Studies**  
*Arlene Siefker-Radtke, University of Texas M.D. Anderson Cancer Center*
- 10:05 a.m. **Discussion**
- 10:15 a.m. **Translational Prospects for Cancer Stem Cells**  
*Vince Cryns, Northwestern University*
- 10:35 a.m. **Discussion**
- 10:45 a.m. **EDRN Validation Study: Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment**  
*Jacob Kagan, National Cancer Institute*
- 11:05 a.m. **Discussion**
- 11:15 a.m. **Break**
- 11:30 a.m. **Second Mitochondrial Activator of Caspase in Bladder Cancer: Implications for Therapy**  
*Ashish Kamat, University of Texas M.D. Anderson Cancer Center*
- 11:50 a.m. **Discussion**

**Breast****Salon V**

- Chairs:* Joe Gray, University of California, San Francisco  
Shelton Earp, III, University of North Carolina at Chapel Hill
- NIH Facilitators:* Karen Johnson, Barbara Vonderhaar, Shamala Srinivas, National Cancer Institute
- 8:00 a.m. **A Phase II Trial of GW57201 for Brain Metastases in Patients With HER-2-Overexpressing Breast Cancer**  
*Nancy Li, Dana-Farber/Harvard Cancer Center*
- 8:30 a.m. **Assessment of Immune Responses to an Autologous Breast Cancer Vaccine**  
*Karen Anderson, Dana-Farber/Harvard Cancer Center*
- 9:00 a.m. **A Phase I/II Trial of BAY 43-9006 (Sorafenib) and Anastrozole in Patients With Metastatic Breast Cancer**  
*Peter Lebowitz, Georgetown University*
- 9:30 a.m. **Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-negative, PR-negative, HER-2 Nonoverexpressing Metastatic Breast Cancers: Emphasis on Use of Circulating Tumor Cells To Follow Clinical Trial Response**  
*Lisa Carey, University of North Carolina at Chapel Hill*  
*Hope Rugo, University of California, San Francisco*
- 10:00 a.m. **Phase II Trial of CCI-779 in Breast Cancer**  
*Gini Fleming, University of Chicago*
- 10:30 a.m. **Markers of Short-Term Contralateral Breast Cancer Risk in Women With a History of Sporadic Breast Cancer**  
*Victoria Seewaldt, Duke University*
- 11:00 a.m. **Phase I Study of Docetaxel/ST1571 in Breast Cancer**  
*Antonio Wolff, Johns Hopkins University*
- 11:30 a.m. **Understanding Breast Cancer Profiles and Risk Factors in Hispanic/Latina Women**  
*Elena Martinez, University of Arizona*

**Gastrointestinal/Pancreas****Salons III & IV**

*Chairs: Scott Kern, Johns Hopkins University  
James Abbruzzese, University of Texas  
M.D. Anderson Cancer Center*

*NIH Facilitators: Mukesh Verma, Paul Wagner, National  
Cancer Institute*

8:00 a.m. **Greetings**  
*Scott Kern, Johns Hopkins University  
James Abbruzzese, University of Texas  
M.D. Anderson Cancer Center  
Ivan Ding, National Cancer Institute*

**8:10 a.m. SPORE Progress Reports 2005-2006**

8:10 a.m. **Johns Hopkins University GI SPORE**  
*Scott Kern, Johns Hopkins University*

8:20 a.m. **University of Arizona GI SPORE**  
*Eugene Gerner, University of Arizona*

8:30 a.m. **Vanderbilt University GI SPORE**  
*Robert Coffey, Vanderbilt University*

8:40 a.m. **University of North Carolina at Chapel  
Hill GI SPORE**  
*Joel Tepper, University of North Carolina at  
Chapel Hill*

8:50 a.m. **Mayo Clinic, Rochester, Pancreatic  
SPORE**  
*Gloria Petersen, Mayo Clinic, Rochester*

9:00 a.m. **University of Texas M.D. Anderson  
Cancer Center Pancreatic SPORE**  
*James Abbruzzese, University of Texas  
M.D. Anderson Cancer Center*

9:10 a.m. **University of Alabama at Birmingham  
Pancreatic SPORE**  
*Selwyn Vickers, University of Alabama at  
Birmingham*

**9:20 a.m. Breakout Discussions****Molecular Epidemiology***Moderator: Gloria Petersen, Mayo Clinic, Rochester***Clinical Trials and Targeted Therapy***Moderator: Jordan Berlin, Vanderbilt University***Preclinical Animal Models***Moderator: Selwyn Vickers, University of Alabama at Birmingham***Tissue Resources and Early Detection***Moderator: Wilma Lingle, Mayo Clinic, Rochester*10:05 a.m. **Break**10:20 a.m. **Reports From Breakout Discussions****10:50 a.m. Special Presentations**10:50 a.m. **A Kras/Smad Knockout Animal Model of Pancreatic Cancer***Chris Klug, University of Alabama at Birmingham*11:00 a.m. **Expression and Alternative Pathways for EGFR and Its Ligands in GI Cancer***David Threadgill, University of North Carolina at Chapel Hill*11:10 a.m. **From Vav1 Basic Science to a GSK3B Inhibitor Preclinical Model***Dan Belladeau, Mayo Clinic, Rochester*11:20 a.m. **Application and Development of Colonography for Colorectal Cancer Screening***Peter Lance, University of Arizona*11:30 a.m. **ER Stress as a Therapeutic Target for Pancreatic Cancer***David McConkey, University of Texas M.D. Anderson Cancer Center*11:40 a.m. **New Immunologic Therapeutics in Pancreatic Cancer***Daniel Laheru, Johns Hopkins University*11:50 a.m. **Combined Inhibition of EGFR and Src in Intestinal Neoplasia***Nipun Merchant, Vanderbilt University*

**Kidney****Salon II**

- Chair: Michael Atkins, Dana-Farber/Harvard Cancer Center*
- 8:00 a.m. **New Information About Hereditary RCC**  
*W. Marston Linehan, National Cancer Institute*
- 8:25 a.m. **Methylated DNA as Biomarkers for Early Detection**  
*Paul Cairns, Fox Chase Cancer Center*
- 8:50 a.m. **Predictive Markers for Response to IL-2, Sorafenib, and CCI-779**  
*Sabina Signoretti, Dana-Farber/Harvard Cancer Center*
- 9:15 a.m. **VHL as a Predictive Marker in RCC**  
*Robert Figlin, University of California, Los Angeles*
- 9:40 a.m. **Pathologic Approaches to RCC Tumor Analysis**  
*Steve Hewitt, National Cancer Institute*
- 10:05 a.m. **Break**
- 10:20 a.m. **Neoadjuvant Protocols**  
*Eric Jonasch, University of Texas M.D. Anderson Cancer Center*
- 10:45 a.m. **RFA and Antiangiogenic Therapy**  
*S. Nahum Goldberg, Dana-Farber/Harvard Cancer Center*
- 11:10 a.m. **Phase I Trial of Sorafenib and Bevacizumab**  
*Jeff Sosman, Vanderbilt University School of Medicine*
- 11:35 a.m. **AKT Inhibitor Perifosine in RCC**  
*I. Craig Henderson, Keryx Biopharmaceuticals*



**Lung**

**Salon VI**

*Chairs: Jill Siegfried, University of Pittsburgh  
Paul Bunn, Jr., University of Colorado  
Health Sciences Center*

*NIH Facilitators: Linda Weiss, Jim Jacobson, Tracy Lively,  
National Cancer Institute*

**8:00 a.m. Updates From Lung Cancer SPORE Studies**

*Jill Siegfried, University of Pittsburgh*

8:00 a.m. **Identification and Validation of Potential Prognostic Markers in Resected Non-Small Cell Lung Cancer**  
*Baogang Xu, Vanderbilt-Ingram Cancer Center*

8:15 a.m. **Multiplexing Approach for Early Diagnosis of Lung Cancer**  
*Anna Lokshin, University of Pittsburgh Cancer Institute*

8:30 a.m. **The Transcription Factor C/EBP alpha in Lung Development and Cancer**  
*Daniel Tenen, Dana-Farber/Harvard Cancer Center*

8:45 a.m. **Identification and Characterization of Human Lung Cancer Stem Cells**  
*Sofia Honoria, University of Texas*

**9:00 a.m. Status of Chemoprevention in Lung Cancer**

*Paul Bunn, Jr., University of Colorado Health Sciences Center*

9:00 a.m. **Overview**  
*Paul Bunn, Jr., University of Colorado Health Sciences Center  
John Minna, University of Texas Southwestern Medical Center/M.D.  
Anderson Cancer Center*

9:10 a.m. **Administration/Data Safety and Monitoring**  
*Paul Bunn, Jr., University of Colorado Health Sciences Center  
John Minna, University of Texas Southwestern Medical Center/M.D.  
Anderson Cancer Center*

- 9:20 a.m.    **Electronic Data Capture and Data Management**  
*Mary Jackson, University of Colorado Cancer Center*
- 9:30 a.m.    **Pathology**  
*Wilbur Franklin, University of Colorado Cancer Center*
- 9:40 a.m.    **Biomarkers**  
*Fred Hirsch, University of Colorado Cancer Center*
- 9:50 a.m.    **Endpoints/Statistics**  
*John Kittelson, University of Colorado Cancer Center*
- 10:05 a.m.    Agents Under Study**
- 10:05 a.m.    **Iloprost**  
*Robert Keith, University of Colorado Cancer Center*  
*York Miller, University of Colorado Cancer Center*
- 10:20 a.m.    **COX-2 Inhibitor**  
*Steven Dubinett, University of California, Los Angeles*  
*Jenny Mao, University of California, Los Angeles*
- 10:35 a.m.    **5-LOX Inhibitor**  
*Omer Kucuk, Karmanos Cancer Institute*
- 10:50 a.m.    **Green Tea**  
*Stephen Lam, British Columbia Cancer Agency*
- 11:05 a.m.    **MDA Trials**  
*Jonathan Kurie, University of Texas M.D. Anderson Cancer Center*
- 11:20 a.m.    **MDA DOD Program**  
*Edward Kim, University of Texas M.D. Anderson Cancer Center*
- 11:35 a.m.    **NCI Portfolio**  
*Eva Szabo, National Cancer Institute*
- 11:50 a.m.    Steps Forward**
- Grant Mechanisms**  
*Peter Ujhazy, National Cancer Institute*  
*John Minna, University of Texas Southwestern Medical Center/M.D. Anderson Cancer Center*  
*Paul Bunn, Jr., University of Colorado Health Sciences Center*

**Ovarian/Gynecologic**

**Salons IX & X**

*Chair: Robert Bast, University of Texas  
M.D. Anderson Cancer Center*

*NIH Facilitators: Ted Trimble, Michael Birrer, National  
Cancer Institute*

8:00 a.m. **Prostate, Lung, Colorectal, and Ovarian  
Screening Trial/Early Detection  
Research Network  
Status Report**

8:30 a.m. **Interim Report: Avon  
Status Report**

9:00 a.m. **Gynecologic Oncology Group (GOG)  
SPORE  
Status Report**

9:30 a.m. **Proteomics Trial  
Status Report  
Inventory of SPORE Labeling/Specimen  
Shipping**

10:00 a.m. **Executive Luncheon  
Discuss Specific Issues Related to Ovarian  
SPOREs**

10:30 a.m. **Future Collaborations  
Potential Collaborations Related to Risk/  
Prevention  
GOG-SPORE Translational Research  
Committee**

**SPORE Directors' and Patient  
Advocates' Working Luncheon  
(invitation only)**

**12 noon - 2:00 p.m.**

**Waterview Ballroom**

**Monday, July 17**

## Organ Site Breakout Session I

**2:00 p.m. - 6:00 p.m.**

These breakout sessions allow organ site programs to discuss (1) the most important recent scientific advancements, (2) opportunities and technologies that can be used to advance the field, (3) collaborations with other SPORE or NCI programs and networks, (4) infrastructures needed to support Inter-SPORE collaborations, and (5) proposed focused activities for upcoming fall or winter meetings.

### Brain

### Salons IX & X

*Chair: Brian Patrick O'Neill, Mayo Clinic, Rochester*

*NIH Jane Fountain, National Institute of*

*Facilitators: Neurological Disorders and Stroke  
Malcolm Smith, Brian Wojcik, National Cancer Institute*

2:00 p.m. **Biostatistics and Bioinformatics**  
*Kathleen Lamborn, University of California, San Francisco*

2:30 p.m. **Pathology**  
*Caterina Giannini, Mayo Clinic, Rochester*

3:00 p.m. **Epidemiology**  
*Ping Yang, Mayo Clinic, Rochester*

3:30 p.m. **Basic/Translational Research Resources**  
*Francis Ali-Osman, Duke University*

4:00 p.m. **Preclinical Resources and Clinical Development of Research Projects**  
*Burt Nabors, University of Alabama at Birmingham*

4:30 p.m. **Status of Request for Supplemental Funds**  
*Peter Ujhazy, National Cancer Institute*

4:40 p.m. **Discussion/Workshop**  
**Drug Development**  
*John Parks, University of California, San Francisco*

**Collaborative Efforts**

6:00 p.m. **Adjournment**

**Head/Neck and Cervical****Salons III & IV**

- Chairs:* Gary Clayman, University of Texas  
M.D. Anderson Cancer Center  
T.C. Wu, Johns Hopkins University
- NIH Facilitators:* Yasaman Shirazi, National Institute of Neurological Disorders and Stroke  
Scott Saxman, National Cancer Institute
- 2:00 p.m. **Novel Cancer Therapy Elicits Tumor-Specific Immunity and Antiangiogenesis: Clinical Implications for HPV-16 Associated Oropharyngeal Head and Neck Cancer Patients**  
*Sara Pai, Johns Hopkins University*
- 2:25 p.m. **Characterization of the Immunomic Profile of Head and Neck Cancer**  
*Nisha D'Silva, University of Michigan*
- 2:50 p.m. **Discussion**
- 3:05 p.m. **Genetic Susceptibility to Head and Neck Cancer**  
*Emanuela Taioli, University of Pittsburgh*
- Targeting EGFR With Antisense Oligonucleotides**  
*Sufi Thomas, University of Pittsburgh*
- 3:30 p.m. **Highlights of Collaborative Studies**  
*David Sidransky, Johns Hopkins University*
- 3:55 p.m. **Discussion**
- 4:10 p.m. **Soy Isoflavones in Head and Neck and Pancreatic Cancer**  
*Omer Kucuk, University of Texas M.D. Anderson Cancer Center*
- 4:35 p.m. **Reverse Phase Protein Arrays**  
*Gordon Mills, University of Texas M.D. Anderson Cancer Center*
- 5:00 p.m. **Discussion**
- 5:15 p.m. **Preclinical Development of Bradykinin Receptor Antagonist Dimer CU201**  
*Dan Chan, University of Colorado*

5:40 p.m. **LOH Validation Testing**  
*Miriam Rosin, University of British Columbia*

6:05 p.m. **Pathology Working Group Updates**  
*Adel El-Naggar, University of Texas M.D. Anderson Cancer Center*

6:15 p.m. **Discussion**

---

**Hematological Malignancies**

**Salon VIII**

*Chairs: Jean-Pierre Issa, University of Texas M.D. Anderson Cancer Center  
 George Weiner, University of Iowa Holden Comprehensive Cancer Center*

*NIH Facilitator: Geraldina Dominguez, National Cancer Institute*

2:00 p.m. **Bayesian Clinical Trial Designs**  
*Donald Berry, University of Texas M.D. Anderson Cancer Center*

2:45 p.m. **Anti-CD20 Antibody Fragments for Optimal Imaging of Lymphoma**  
*Tove Olafsen, University of California, Los Angeles  
 David Betting, University of California, Los Angeles  
 Vania Kenanova, University of California, Los Angeles  
 Andrew Raubitschek, City of Hope Comprehensive Cancer Center  
 John Timmerman, University of California, Los Angeles  
 Anna Wu, University of California, Los Angeles*

3:00 p.m. **Manufacturing of Large Numbers of Gene-Modified T Cells: An Approach to Improving Product Safety While Increasing Production Capacity**  
*Luciana Burton, Chy-Anh Tran, Diana Russom, Jamie Wagner, Michael Jensen, Stephen Forman, David DiGiusto, City of Hope Comprehensive Cancer Center and Beckman Research Institute*

- 3:15 p.m. **Donor CD8<sup>+</sup> T Cells Mediate GVL Without GVHD in Recipients Conditioned With Anti-CD3 mAb**  
*Chunyan Zhang, Jingwei Lou, Nainong Li, Vivian Lin, Stephen Forman, Defu Zeng, City of Hope Comprehensive Cancer Center and Beckman Research Institute*
- 3:30 p.m. **Antigen Detection in Diffuse Large B Cell Primary Central Nervous System Lymphoma: Further Clarification of the Role of SV40 Large T Antigen in Tumorigenesis**  
*Brian Patrick O'Neill, Ricardo Lloyd, Jennie Goble, Caterina Giannini, Stephen Ansell, Thomas Witzig, Mayo Clinic, Rochester*
- 3:45 p.m. **A First-in-Human Clinical Trial of Adoptive Therapy Using Cd19-Specific Chimeric Antigen Receptor Redirected T Cells for Recurrent/Refractory Follicular Lymphoma**  
*Michael Jensen, Leslie Popplewell, David DiGiusto, Michael Kalos, Laurence Cooper, Andrew Raubitschek, Stephen Forman, City of Hope Comprehensive Cancer Center and Beckman Research Institute*
- 4:00 p.m. **A Phase I Study of Humanized Anti-CD20-IL2 Immunocytokine in Patients With B Cell Non-Hodgkin's Lymphoma**  
*Ryotaro Nakamura, Auayporn Nademanee, Michael Kalos, David Colcher, Paul Frankel, Stephen Forman, Andrew Raubitschek, City of Hope Comprehensive Cancer Center and Beckman Research Institute*
- 4:15 p.m. SPORE Updates - Bench to Bedside**
- 4:15 p.m. *Jean-Pierre Issa, University of Texas M.D. Anderson Cancer Center*
- 4:35 p.m. *Richard Ambinder, Johns Hopkins University*
- 4:55 p.m. *George Weiner, Thomas Witzig, University of Iowa Holden Comprehensive Cancer Center/Mayo Clinic*
- 5:15 p.m. *Stephen Forman, City of Hope Comprehensive Cancer Center and Beckman Research Institute*
- 5:35 p.m. *Kenneth Anderson, Dana-Farber/Harvard Cancer Center*

**Prostate****Salon V**

- Chairs:* Kenneth Pienta, University of Michigan  
 Christopher Logothetis, University of Texas  
 M.D. Anderson Cancer Center  
 Philip Kantoff, Dana-Farber Cancer Institute
- NIH Facilitators:* Alison Martin, William Figg, William Dahut,  
 Suresh Mohla, National Cancer Institute
- 2:00 p.m. **XPD (ERCC-2) and Prostate Cancer: Susceptibility Depends on the Degree of DNA Damage and Transcriptional Interference**  
*Brett Carver, Memorial Sloan-Kettering Cancer Center*
- 2:15 p.m. **Characterization of the TMPRSS2: ERG Gene Fusion Prostate Cancer**  
*Mark Rubin, Dana-Farber/Harvard Cancer Center*
- 2:30 p.m. **Toward a Suite of DNA-Based Prostate Cancer Biomarkers for Clinical Diagnostics and Drug Targets**  
*Colin Collins, University of California, San Francisco*
- 2:45 p.m. **Prostate-Specific Antigen Screening and Reduced Prostate Cancer Mortality**  
*Iliir Agalliu, Fred Hutchinson Cancer Research Center*
- 3:00 p.m. **Reactive Stroma in Prostate Cancer Progression**  
*Gustavo Ayala, Baylor College of Medicine*
- 3:15 p.m. **Molecular Analysis of the Prostate Tumor Microenvironment**  
*Annely Richardson, Howard Hughes Medical Institute*
- 3:30 p.m. **Integrated Microfluidic Circuits for Dynamic Analysis of P13K Signaling Pathway Markers**  
*Hsian-Rong Tseng, University of California, Los Angeles*
- 3:45 p.m. **Break**



- 4:00 p.m. **Expression of Inhibitory B7 Molecules in Prostate Cancer**  
*James Allison, Memorial Sloan-Kettering Cancer Center*
- 4:15 p.m. **Targeted Drug Delivery to Prostate Cancer Cells Using Internalizing scFv Against MEMD**  
*James Marks, University of California, San Francisco, Comprehensive Cancer Center*
- 4:30 p.m. **Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: PSADT Subgroups and Their Associated Contributions to All-Cause Mortality**  
*Stephen Freedland, Johns Hopkins University*
- 4:45 p.m. **The Isopeptidase USP2a Protects Human Prostate Cancer From Apoptosis**  
*Carmen Priolo, Dana-Farber Cancer Institute*
- 5:00 p.m. **Nanoparticle-Aptamer Bioconjugates for Targeted Prostate Cancer Chemotherapy In Vivo**  
*Omid Farokhzad, Brigham and Women's Hospital*
- 5:15 p.m. **Multimodality Nanoparticle Targeting Prostate Cancer**  
*Fanqing Frank Chen, Lawrence Livermore National Laboratory*
- 5:30 p.m. **Ligand-Directed Molecular Imaging in Prostate Cancer: Implications for Diagnosis and Therapy**  
*Wadih Arap, University of Texas M.D. Anderson Cancer Center*

**Skin****Salons I & II**

*Chair:* Meenhard Herlyn, The Wistar Institute

*NIH Facilitator:* Magdalena Thurin, National Cancer Institute

2:00 p.m. **Introduction**  
*Meenhard Herlyn, The Wistar Institute*

- 2:15 p.m. **Tissue Arrays**  
*David Elder, The Wistar Institute/University of Pennsylvania*  
*Victor Prieto, University of Texas*  
*M.D. Anderson Cancer Center*  
*Lyn Duncan, Harvard University*
- 2:45 p.m. **Discussion on Future Arrays, Validations, and Prioritization of Marker Testing**
- 3:15 p.m. **Genomics, Platform Sharing**  
*Lynda Chin, Harvard University*  
*Kate Nathanson, The Wistar Institute/University of Pennsylvania*  
*Jeffrey Gershenwald, University of Texas*  
*M.D. Anderson Cancer Center*
- 3:45 p.m. **Discussion of Future Plans**
- 4:00 p.m. **Break**
- 4:15 p.m. **Clinical Trials**  
*Ravi Amatavani, The Wistar Institute/University of Pennsylvania*  
*Mario Sznol, Yale University*  
*Patrick Hwu, University of Texas*  
*M.D. Anderson Cancer Center*
- 4:45 p.m. **SPORE Collaborative Trials**  
*Mike Atkins, Harvard University*  
*Lynn Schuchter, The Wistar Institute/University of Pennsylvania*
- 5:05 p.m. **Discussion**
- 5:15 p.m. **Preclinical Trial Preparation and Treatment Followup Studies**  
*Keith Flaherty, The Wistar Institute/University of Pennsylvania*  
*Kevin Kim, University of Texas*  
*M.D. Anderson Cancer Center*  
*Keiran Smalley, The Wistar Institute/University of Pennsylvania*  
*Allen Bale, Yale University*
- 5:45 p.m. **Discussion**
- 5:55 p.m. **Future Meetings**

## **Meet-the-Author Poster Session and Dinner Buffet**

**6:00 p.m. - 9:00 p.m.**

**Harborside Ballroom**

**Internet Room**

7:00 a.m. - 7:00 p.m.

**Atlantic****Speaker Ready Room**

7:00 a.m. - 7:00 p.m.

**Bristol****Registration**

7:00 a.m. - 7:00 p.m.

**Grand Registration Desk****Industry Learning Centers**

See pages 3-5 for times and locations.

**Early Morning Break**

7:00 a.m. - 8:00 a.m.

**Various Locations****Prostate SPOREs Directors' Meeting  
(invitation only)**

7:00 a.m. - 8:00 a.m.

**Boardroom****Poster Session**

8:00 a.m. - 6:00 p.m.

**Harborside Ballroom**

This session will offer investigators and industry the opportunity to present and share exciting research projects in an interactive forum. One-on-one interactions, networking, and discussions are highly encouraged in order to facilitate partnerships and collaborations.

## Intellectual Property Management: Technology Transfer

**8:00 a.m. - 10:00 a.m.**

**Salon V**

This session will offer training for all SPORE investigators and interested individuals in IP management, technology transfer, and related topics. The session will include a panel discussion with experts in the field. Participants are encouraged to bring their personal experience, solutions to problems, and questions. The goal is to educate and discuss solutions to problems that hamper successful translational research in cancer.

*Panelists:* Karen Maurey, National Cancer Institute  
 Anthony Del Campo, Dana-Farber/Harvard Cancer Center  
 Stewart Davis, Baylor College of Medicine  
 Jack Roth, University of Texas M.D. Anderson Cancer Center  
 Gregory Curt, AstraZeneca  
 Brian Voyce, Intellectual Property Practitioner

- 8:00 a.m.    **Introduction and Main Concepts of IP Management**  
*Karen Maurey, National Cancer Institute*
- 8:15 a.m.    **Collaboration, Technology Transfer, and Commercialization**  
*Anthony Del Campo, Dana-Farber/Harvard Cancer Center*
- 8:25 a.m.    **Experience of a SPORE Investigator in Terms of Academia and Pharma Interaction**  
*Jack Roth, University of Texas M.D. Anderson Cancer Center*
- 8:35 a.m.    **IP Management: Industry Perspective**  
*Gregory Curt, AstraZeneca*
- 8:45 a.m.    **Beware Conflicting IP and FDA Regulatory Arguments or *How Speaking With a "Forked Tongue" May Knife Your IP Assets***  
*Brian Voyce, Intellectual Property Practitioner*
- 8:55 a.m.    **Session Wrap-up**  
*Stewart Davis, Baylor College of Medicine*
- 9:00 a.m.    **Panel Discussion and Q&A Session**

## DHHS Cross-cutting Initiatives I

**8:00 a.m. - 10:00 a.m.**

These concurrent sessions will address DHHS initiatives targeting research in specific groundbreaking areas. Session topics are (1) FDA Critical Paths and (2) Image-Guided Serial Tissue Acquisition. DHHS staff will present strategic plans of the initiatives alongside scientists and experts giving scientific presentations, with the objective of informing SPORE investigators and other participants about new research opportunities as well as possibilities for coordination with these funded research initiatives.

### FDA Critical Paths

### Salons I-IV

This session will describe the FDA's Critical Pathway Initiative (CPI) and the related activities of the Oncologic Biomarker Qualification Initiative (OBQI) involving NCI, FDA, and the Centers for Medicare and Medicaid Services. CPI is the FDA's premier initiative to identify and prioritize the most pressing medical product development problems and the greatest opportunities for rapid improvement in public health benefits. During this session, Dr. Janet Woodcock of the FDA and Dr. Gary Kelloff of NCI will present an overview of the CPI and the OBQI with case study examples. Selected speakers will discuss the opportunities and challenges of developing imaging and molecular targeted diagnostic assays to enhance oncologic drug development and improve the care of the cancer patient.

*Chairs: Janet Woodcock, U.S. Food and Drug Administration  
Gary Kelloff, National Cancer Institute*

8:00 a.m. **FDA Critical Path Initiative: Implications for Cancer Research**  
*Janet Woodcock, U.S. Food and Drug Administration*

8:15 a.m. **Oncologic Biomarker Qualification Initiative: Opportunities for Progress in Development of Imaging and Assays of Molecular Targets**  
*Gary Kelloff, National Cancer Institute*

8:30 a.m. **Presentations**

Developing Predictive Diagnostic Tests for Targeted Therapies for Patients With Cancer—Triumphs and Challenges  
*Paul Waring, Genentech*

A Novel Pheno/Genotypic Assay for Comprehensive Delineation of HER2 Status in Breast Carcinoma  
*Raymond Tubbs, Cleveland Clinic*

The Critical Path Initiative—The Importance of Collaboration  
*Ray Woosley, C-Path Institute*

Translating the Discovery of Alterations in the EGFR Into the Targeted Treatment of Patients With Lung Cancer  
*Bruce Johnson, Dana-Farber Cancer Institute*

9:30 a.m. **Roundtable Discussion**

*Moderator: David Parkinson*

*Felix Frueh, U.S. Food and Drug Administration (additional panelist)*

---

**Image-Guided Serial Tissue Acquisition**
**Salon VI**

Targeted therapy development is increasingly implementing correlative evaluation of tissue markers for the assessment of agent efficacy. The advent of image-guided serial tissue acquisition (IGSTA) offers a promising new approach for enhancing the ability to discretely acquire high-quality tissue specimens in a relatively noninvasive manner.

This session will focus on the potential benefits and pitfalls associated with image-guided serial tissue acquisition in the setting of early-phase clinical trials. Prior successful experiences with IGSTA in single-institution and multi-institution trials will be presented. This session will be followed by a discussion meeting on the techniques of image-directed biopsies and patient management. Additionally, in "Imaging: Correlation With Biomarkers in Translational Research and Therapy Working Group," there will be discussion of specific clinical trial proposals in which image-guided serial tissue acquisition may be implemented.

*Chairs: John Haaga, Case Western Reserve University  
Nola Hylton, University of California, San Francisco  
Gary Dorfman, National Cancer Institute*

**8:00 a.m. Single Center Case Study: Image-Guided Serial Tissue Acquisition Across Multiple Clinical Trials at Case Western Reserve University**

8:00 a.m. Report From an Active IGSTA Program  
*John Haaga, Case Western Reserve University*

8:30 a.m. Value From a "Customer" Perspective  
*Afshin Dowlati, Case Western Reserve University*

**8:45 a.m. Multi-Center Trial Case Study: The I-SPY Collaboration Among the Breast SPOREs, CALGB, and ACRIN**

8:45 a.m. Image-Guided Tissue Acquisition in I-SPY  
*Nola Hylton, University of California, San Francisco*

8:55 a.m. I-SPY: Why Serial Tissue Acquisition?  
*Laura Esserman, University of California, San Francisco*

9:05 a.m. Improving Tissue Specificity With MRI  
*Mark Rosen, Hospital of the University of Pennsylvania*

9:15 a.m. Panel Discussion

---

## Mini-symposia

**10:15 a.m. - 12:15 p.m.**

These concurrent sessions will allow investigators to present and elicit discussions on new findings, methodologies, agents, and mechanisms that may alleviate the incidence and mortality of human cancer.

### **Cancer and Inflammation**

**Dover A-C**

Chronic inflammation has long been suggested to constitute a risk factor for a variety of malignancies. An inflammatory process is typically accompanied by generation of free radicals, overproduction of cytokines, growth factors, and angiogenic factors. Free radical-mediated DNA damage contributes to the tumor initiation. Cytokines and growth factors can further promote tumor growth by stimulating cell proliferation, adhesion, and vascularization. Recent data have expanded the concept of inflammation as a critical component in carcinogenesis, suggesting new anti-inflammatory therapies for a complementary approach in treating a variety of tumor types.

*Chairs: Steven Dubinett, University of California, Los Angeles  
Jonathan Serody, University of North Carolina at Chapel Hill  
Angelo De Marzo, Johns Hopkins University*

10:15 a.m. **Inflammation and Modulation of Early Cancer Phenotypes**

*Thea Tlsty, University of California, San Francisco*

10:30 a.m. **Discussion**

10:35 a.m. **Sp/XKLF Proteins and Human Pancreatic Cancer Biology and Therapy**

*Keping Xie, University of Texas M.D. Anderson Cancer Center*

10:50 a.m. **Discussion**

10:55 a.m. **Role of the Tumor Microenvironment in the Promotion of Alveolar Epithelial Neoplasia Induced by Oncogenic KRAS**

*John Kurie, University of Texas M.D. Anderson Cancer Center*



- 11:10 a.m. Discussion
- 11:15 a.m. Inflammation-Mediated Promotion of EMT in Non-Small Cell Lung Cancer: IL-1 $\beta$  and PGE2 Induced Transcriptional Repressors ZEB1 and Snail Leading to Down-Regulation of E-Cadherin  
*Steven Dubinett, University of California, Los Angeles*
- 11:30 a.m. Discussion
- 11:35 a.m. Activation of Stat3 in Evolving Drug Resistance and Inflammation: A Potential Target for Cancer Therapy  
*Michael Seiden, Massachusetts General Hospital*
- 11:50 a.m. Discussion
- 11:55 a.m. Role of ING4 in Modulating NF- $\kappa$ B Mediated Transcription and Gene Selection  
*Susan Nozell, University of Alabama at Birmingham*
- 12:10 p.m. Discussion

---

### Small Molecules in Cancer Therapy

### Salon V

Development of small molecules aimed against molecular targets in cancer cells represents one of the fastest growing fields in cancer treatment and prevention. Fostered by the recent success stories in the therapy of chronic myeloid leukemia, myeloma, and lung and colon cancer, to name a few, small molecules promise considerable potential in efficacy with minimal adverse effects. The objective of the session is to provide SPORE investigators with a forum to address highlights, exchange experience, and work out problems in this highly dynamic field.

*Chairs: Kenneth Anderson, Dana-Farber Cancer Institute  
Nikhil Munshi, Dana-Farber Cancer Institute*

- 10:15 a.m. Phosphoproteomic Analysis of HER2/neu Signaling and Inhibition  
*Ron Bose, Johns Hopkins University*

- 10:30 a.m. **EGFR Degradation: A Novel Mechanism of Gemcitabine-Induced Cell Death in Head and Neck Cancer Cell Lines**  
*Mukesh Nyati, University of Michigan*
- 10:45 a.m. **Gefitinib Reverses TRAIL Resistance via Inhibition of AKT and XIAP in Human Bladder Cancer Cells**  
*David McConkey, University of Texas M.D. Anderson Cancer Center*
- 11:00 a.m. **Targeting BRAF With Sorafenib in Patients With Metastatic Melanoma: The Penn/Wistar Experience**  
*Lynn Schuchter, University of Pennsylvania*
- 11:15 a.m. **GSK-3 $\beta$  Inhibition Enhances Sorafenib-Induced Apoptosis in Melanoma Cell Lines**  
*David Panka, Beth Israel Deaconess Medical Center*
- 11:30 a.m. **Combined Depletion of Cell Cycle and Transcriptional Cdk Activities Induces Apoptosis in Cancer Cells**  
*Geoffrey Shapiro, Dana-Farber Cancer Institute*
- 11:45 a.m. **Wnt 7a and Fzd 9 Activate PPAR Through an ERK-5 Ligand-Independent Mechanism and Reverse the Transformation of Non-Small Cell Lung Cancer Cells**  
*Robert Winn, University of Colorado Health Sciences Center*
- 12 noon **Direct Antitumor Effects and Profound Reduction in Tumor Metastasis With Selective EP4 Receptor Antagonism**  
*Li Yang, Vanderbilt-Ingram Cancer Center*
-

---

**Tumor Cells and Lineage Dependencies**
**Salons I-IV**

Recent discoveries in a number of organ sites have brought to light the heterogeneous nature of most malignancies and sparked interest in identifying those cells crucial to the survival of the cancer. This session will highlight recent discoveries of tumor stem cells and lineage-specific survival genes and discuss their potential relevance in the development of better cancer diagnostics and therapeutics.

*Chairs: Meenhard Herlyn, The Wistar Institute  
Max Wicha, University of Michigan*

10:15 a.m. **Introduction to Cancer Stem Cells**  
*Max Wicha, University of Michigan*

10:45 a.m. **Discussion**

10:50 a.m. **Cell of Origin Predetermines Phenotype of Breast Tumors**  
*Tan Ince, Brigham and Women's Hospital,  
Harvard Medical School*

11:00 a.m. **Discussion**

11:05 a.m. **Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma**  
*Mark Prince, University of Michigan*

11:15 a.m. **Discussion**

11:20 a.m. **Naked2, a Putative Negative Regulator of Canonical Wnt Signaling and Critical Regulator of TGF $\alpha$  Basolateral Trafficking in Polarized Epithelial Cells, Is Down-Regulated in Colorectal Cancer**  
*Robert Coffey, Vanderbilt University*

11:30 a.m. **Discussion**

11:35 a.m. **Mesenchymal Stem Cells Selectively Engraft Into Tumor Stroma and Confer Potent Antitumor Activity**  
*Michael Andreeff, University of Texas  
M.D. Anderson Cancer Center*

11:50 a.m. **Summary and Discussion**  
*Meenhard Herlyn, The Wistar Institute*

---

**Steroid Hormone Receptors****Salon VI**

Hormone therapy is used extensively in a variety of cancers. The focus of this session will be on the role of steroid hormone receptors as targets in cancer prevention and therapy. The session will also include discussions on mechanistic approaches including modifiers of hormone actions and steroid hormone receptors, new concepts of endocrine resistance, and communication between growth factors and steroid hormone receptor pathways. This interactive session will help in bringing together experts (across organ sites) in these scientific fields to discuss mechanistic concepts and clinical relevance, and how to further advance this field for the management of cancer.

*Chairs: Donald Tindall, Mayo Clinic*

*Jill Siegfried, University of Pittsburgh*

*Moderator: Jill Siegfried, University of Pittsburgh*

10:15 a.m. **“Androgen-Independent” Prostate Cancer Is Not Androgen Independent**  
*James Mohler, Roswell Park Cancer Institute*

10:35 a.m. **Steroid Receptors as Targets of Pro-Inflammatory Signals**  
*David Rose, University of California, San Diego*

10:55 a.m. **SERMs and SARMs: Emerging Roles for Selective Nuclear Receptor Modulators in Cancer**  
*James Dalton, GTx, Inc.*

*Moderator: Donald Tindall, Mayo Clinic*

11:15 a.m. **Targeting Estrogenic Pathways for Lung Cancer Therapy**  
*Jill Siegfried, University of Pittsburgh*

11:30 a.m. **Estrogen Signaling Interacts With Growth Factor Receptor Pathways in Human Non-Small Cell Lung Cancer**  
*Richard Pietras, University of California, Los Angeles*

11:45 a.m. **Role of Androgen Receptor in Tamoxifen Resistance in Breast Cancer**  
*Suzanne Fuqua, Baylor College of Medicine*

12 noon **Antagonists That Enhance Androgen Receptor-NCoR Interaction for Prostate Cancer Therapy**  
*Steven Balk, Beth Israel Deaconess Medical Center*

**Oxidative Stress****Salons VII-X**

There is strong evidence that oxidative stress, generated both intracellularly and extracellularly, is associated with carcinogenesis and cancer progression. Reactive oxygen species (ROS) cause oxidative damage to important biomolecules, such as lipids, proteins, and DNA. Oxidative modification of DNA bases leads to mutation and altered gene function resulting in carcinogenesis. ROS can also induce the expression of many transcriptional factors involved in neoplastic transformation. Germ line polymorphisms in genes related to oxygen metabolism and antioxidant activity are implicated in cancer susceptibility and progression. The goal of the session is to examine new findings and current technologies relating oxidative stress to cancer etiology, therapy, and prevention.

*Chairs: William Nelson, Johns Hopkins University  
Ted Dewese, Johns Hopkins University*

- 10:15 a.m. **Markers of Intracellular Oxidative Stress in Melanoma Tumor Cells Identify the Subset of Melanoma Patients With Shortest Survival**  
*Elizabeth Grimm, University of Texas  
M.D. Anderson Cancer Center*
- 10:30 a.m. **Quantification of Isothiocyanate and Isothiocyanate Metabolites in Human Mammary Tissue After Oral Administration of a Broccoli Sprouts Preparation**  
*Kala Visvanathan, Johns Hopkins University*
- 10:45 a.m. **Smoking, Occupational Exposure, and GSTM1 in AML Survival: Gene-Environment Interaction**  
*Sara Strom, University of Texas  
M.D. Anderson Cancer Center*
- 11:00 a.m. **Polymorphisms of the nNOS and iNOS Genes and Risk of Cutaneous Melanoma: A Case-Control Analysis**  
*Chunying Li, University of Texas  
M.D. Anderson Cancer Center*

- 11:15 a.m.    **Src Kinase Production of ROS via Akt in Myeloid Cells**  
*Seth Corey, University of Texas  
M.D. Anderson Cancer Center*
- 11:30 a.m.    **Pivotal Role of Reactive Oxygen Species and MAP Kinases in Induction of Cell Death Pathways by the Synthetic Retinoid Fenretinide**  
*Reuben Lotan, University of Texas  
M.D. Anderson Cancer Center*
- 11:45 a.m.    **Malondialdehyde-DNA Adducts in Normal Breast Tissues**  
*Ramona Dumitrescu, Georgetown University*

---

### **Executive Luncheon** *(closed meeting)*

---

**11:30 a.m. - 2:30 p.m.**

**Waterview Ballroom**

---

### **Clinical Trials and SPORE Patient Advocates' Luncheon** *(invitation only)*

---

**12:15 p.m. - 2:15 p.m.**

**Laurel A-D**

---

### **Image-Guided Tissue Acquisition: Technical Aspects Working Luncheon** *(bring your own lunch)*

---

**1:00 p.m. - 2:30 p.m.**

**Dover A-C**

---

## Working Groups

**2:30 p.m. - 5:30 p.m.**

These sessions will focus on aspects of the current state of the translational cancer research climate, initiating dialogue and action in these areas.

### **EGFR/HER2 Neu Targeted Therapies      Salons I-IV**

Targeting epidermal growth factor receptor and related molecules led recently to major breakthroughs in the management of cancer. The presence of these targets in high-prevalence diseases such as lung, breast, and colon cancers guarantees major impact across patient populations and thus attracts ample attention from the scientific community and general public. The goals of the session are to invite SPORE leaders in the field to a discussion about new developments in this area, to support collaborative efforts, and to set up new objectives.

*Chairs:*      *Carlos Arteaga, Vanderbilt University*  
                   *Bruce Johnson, Dana-Farber/Harvard*  
                   *Cancer Center*  
                   *Mark Sliwkowski, Genentech, Inc.*

*Patient Advocate Panelist: Cindy Geoghegan*

- 2:30 p.m.      **Introduction**  
                   *Peter Ujhazy, National Cancer Institute*
- 2:35 p.m.      **EGFR/HER Family Gene Mutations and Response to Targeted Therapy**  
                   *Bruce Johnson, Dana-Farber/Harvard Cancer Center*
- 2:50 p.m.      **EGFR/HER Family Gene Amplification as a Predictor to Therapy Response**  
                   *Carlos Arteaga, Vanderbilt University*
- 3:05 p.m.      **Identification of Patients Responsive to EGFR/HER Targeted Therapies**  
                   *Fred Hirsch, University of Colorado Health Sciences Center*
- 3:20 p.m.      **Therapeutic Approaches to Targeting the HER/ErbB Pathway**  
                   *Mark Sliwkowski, Genentech, Inc.*
- 3:35 p.m.      **Panel Discussion and Workshop**

**Methods in Validation of Biomarkers****Salon V**

While a growing number of cancer markers are being discovered, good laboratory practice for the translational phase of biomarker assay development that will provide accurate data for human intervention studies remains to be clearly defined. This Working Group session will address a range of key challenges for enhancing the quality of translational implementation of biomarkers.

*Chairs:* William Bigbee, University of Pittsburgh  
David Sidransky, Johns Hopkins University  
George Klee, Mayo Clinic

*Patient Advocate Panelist:* Sean Patrick

**2:30 p.m. Pre-Analytical Considerations**

2:30 p.m. Quality Control of Fluid Specimens for Biomarker Analysis

*Daniel Chan, Johns Hopkins University*

2:40 p.m. Impact of Pre-Analytic Variation on Tissue Analysis: Issues and Practical Applications

*Angelo DeMarzo, Johns Hopkins University  
Samson Fine, Memorial Sloan-Kettering Cancer Center*

**2:50 p.m. Analytic Validation**

2:50 p.m. Use of CLSI and Similar Guidance Documents for the Validation of Biomarkers

*Russel Enns, Cepheid*

3:00 p.m. In Vitro Diagnostic Assay Product Development and Validation: Industrial and Regulatory Perspective

*Thomas Soriano, DOCRO, Inc.*

3:10 p.m. Analytic Validation: Discovery Perspective

*William Bigbee, University of Pittsburgh*

3:20 p.m. Analytic Validation: Clinical Laboratory Perspective

*Herbert Fritsche, University of Texas  
M.D. Anderson Cancer Center*

3:30 p.m. Panel Discussion



**4:15 p.m. Clinical Validation**

4:15 p.m. **Challenges of Biomarker Validation for Early Detection**  
*David Sidransky, Johns Hopkins University*

4:25 p.m. **Challenges of Biomarker Validation in Clinical Trials**  
*Gordon Mills, University of Texas  
 M.D. Anderson Cancer Center*

4:35 p.m. **Biomarker Confirmation: Bridging Discovery to Clinical Validation**  
*George Klee, Mayo Clinic*

4:45 p.m. **Panel Discussion**

---

**Imaging: Correlation With Biomarkers      Salon VI  
 in Translational Research and Therapy**

Major technology advancements in imaging techniques during the last decade led to unprecedented opportunities in screening, diagnosis, and prediction of outcomes in cancer. In parallel, the development of cancer biomarkers also marked considerable progress. Merging imaging with biomarkers in a concerted effort improves the ability to control the disease at every stage. Today, several clinical intervention trials take advantage of these rather complex monitoring tools. The objective of this session is to discuss the use of molecular, cellular, and histologic markers in combination with imaging techniques as detection technologies for early detection and diagnosis as well as in the context of therapies.

*Chairs: Gary Kelloff, National Cancer Institute  
 Peter Choyke, National Cancer Institute  
 Juri Gelovani, University of Texas  
 M.D. Anderson Cancer Center*

*Patient Advocate Panelist: Lori Monroe*

2:30 p.m. **Overview of Biomarkers and Imaging To Accelerate Oncologic Drug Development**  
*Gary Kelloff, National Cancer Institute*

3:10 p.m. **Imaging Biomarkers for Selection and Monitoring of Targeted Therapies**  
*Juri Gelovani, University of Texas  
 M.D. Anderson Cancer Center*

- 3:50 p.m. **The Role of MRI in Cancer Treatment Trials: Opportunities and Challenges**  
*Peter Choyke, National Cancer Institute*
- 4:30 p.m. **Molecular Imaging for Drug Discovery and Development**  
*Wafik El-Deiry, University of Pennsylvania*
- 5:10 p.m. **Discussion and Next Steps**

---

## **Clinical Trial Design in Translational Research**

## **Salons VII-X**

There is a trend of increasing use of randomized Phase II designs in cancer therapy. Continued improvement in study design, conduct, analysis, and reporting is required to enhance the quality of clinical trials at different phases. The accrual rate and success rate of the trials remain low, and therefore, futility stopping rules to terminate ineffective treatment arm(s) should be implemented more frequently. More innovative, flexible designs for Phase II trials are needed to facilitate the development of effective cancer treatments. This section will discuss and explore the challenges faced in designing high-quality clinical trials in cancer therapies. What can we do to better predict the success of a therapeutic in a clinical trial from the preclinical modeling? Investigators from industry, academia, FDA, and NCI will present their experience in this field.

*Chairs:* *Christopher Logothetis, University of Texas  
M.D. Anderson Cancer Center*  
*Robert Figlin, University of California,  
Los Angeles*  
*Donald Berry, University of Texas  
M.D. Anderson Cancer Center*  
*H. Kim Lyerly, Duke University*  
*David Parkinson, Biogen Idec*

*Patient Advocate Panelist: Bill Blair*

- 2:30 p.m. **Introduction**  
*Christopher Logothetis, University of Texas  
M.D. Anderson Cancer Center*

**Session I: Moderator: Christopher Logothetis, University of Texas M.D. Anderson Cancer Center**

2:35 p.m. Opportunities: Clinical Trial Design Driven by New Methodology and Technology  
*Donald Berry, University of Texas M.D. Anderson Cancer Center*

3:05 p.m. Panel Discussion

**Session II: Moderator: H. Kim Lyerly, Duke University**

3:20 p.m. Phase Zero Trials: Settings for Their Application and Establishment of Early Proof of Principle, Role in Drug Development  
*Anthony Murgo, National Cancer Institute*

3:35 p.m. Embedding Marker Development and Validation in the Context of Clinical Studies  
*Robert Figlin, University of California, Los Angeles*

3:50 p.m. Challenge of Evolution From Phase II to Phase III  
*Meg Mooney, National Cancer Institute*

4:05 p.m. Panel Discussion

**Session III: Moderators: Donald Berry, University of Texas M.D. Anderson Cancer Center, and Bill Blair, Patient Advocate**

4:25 p.m. Development of a Clinical Investigation Process To Support the Development of Patient Management Strategies  
*Christopher Logothetis, University of Texas M.D. Anderson Cancer Center*

4:40 p.m. Developing Chemopreventive Agents (Embedding Prevention Strategies in Treatment Trials)  
*Scott Lippman, University of Texas M.D. Anderson Cancer Center*

- 4:55 p.m. **Industry Perspective (Methods To Accelerate Early Clinical Validation of New Concepts and Agents): Role of Animal Models in Drug Development**  
*David Parkinson, Biogen Idec*
- 5:10 p.m. **Panel Discussion**

## FDA Regulatory Issues

**5:45 p.m. - 7:45 p.m.**

**Salons I-IV**

This forum, a companion session to the Intellectual Property Management session, will address regulatory issues facing translational research in a format that encourages participation by NCI and FDA representatives in the framework of presentations and panel discussions, providing educational and problem-solving opportunities.

*Panelists:* *Carolyn Wilson, U.S. Food and Drug Administration*  
*Patricia Keegan, U.S. Food and Drug Administration*  
*Steve Gutman, U.S. Food and Drug Administration*  
*Joseph Tomaszewski, National Cancer Institute*

**5:45 p.m. Presentations**

- 5:45 p.m. **Development of Novel Cellular and Gene Therapy Cancer Treatments: Emerging Regulatory Themes**  
*Carolyn Wilson, U.S. Food and Drug Administration*
- 6:00 p.m. **Pitfalls To Watch For in Drug Development: An FDA Perspective**  
*Patricia Keegan, U.S. Food and Drug Administration*
- 6:15 p.m. **FDA Regulation of In Vitro Diagnostic Devices—Regulatory Tools for Navigating the Critical Path**  
*Steve Gutman, U.S. Food and Drug Administration*
- 6:30 p.m. **Regulatory Issues Surrounding the Exploratory IND and Phase 0 Clinical Trials**  
*Joseph Tomaszewski, National Cancer Institute*
- 6:45 p.m. **Panel Discussion**

## DHHS Cross-cutting Initiatives II

**5:45 p.m. - 7:45 p.m.**

These concurrent sessions will address DHHS initiatives targeting research in specific groundbreaking areas. Session topics are (1) Nanotechnology, Proteomics, and Genomics and (2) NIH Roadmap Initiative. DHHS staff will present strategic plans of the initiatives alongside scientists and experts giving scientific presentations, with the objective of informing SPORE investigators and other participants about new research opportunities as well as possibilities for coordination with these funded research initiatives.

### **Nanotechnology, Proteomics, and Genomics**

**Salon V**

*Nanotechnology.* NCI has formed the Nanotechnology Alliance to harness the power of nanotechnology to radically change the way we diagnose, image, and treat cancer. The Alliance is a comprehensive program consisting of interdisciplinary centers and individual research and training projects targeting nanotechnology solutions for improved prevention, detection, and therapy of cancer. It also has an intramural laboratory component—Nanotechnology Characterization Laboratory—that provides the nanomaterial characterization services to accelerate the transition of basic nanoscale particles and devices into clinical applications. Two presentations will provide the recent science and technology highlights from the work of the Alliance centers.

*Proteomics.* In order to develop and better standardize technologies used to identify proteins and peptides in complex specimen mixtures, NCI established the Mouse Proteomic Technologies Initiative. Participants in this session will learn how NCI is developing new tools, reagents, protocols, and new mouse cancer models that better mimic human response and permit accurate and reproducible measurements of proteins/peptides, in the belief that proteomics will play a major role in future health care in the prediction, prevention, and treatment of disease at a personal level.

*Genomics.* NCI and the National Human Genome Research Institute initiated a 3-year pilot project, The Cancer Genome Atlas (TCGA), to determine the feasibility of cataloging the genomic alterations associated with a set of human cancers. The overall aim of TCGA initiative is to accelerate the understanding of the molecular basis of cancer through the development and application of high-resolution, high-throughput genome analysis technologies using human cancer biospecimens. The pilot project will also verify whether cancer-associated genes and/or genomic regions can be identified by combining information from genome analyses with tumor biology and clinical data. Collectively, genomic and clinical data generated will provide the initial contributions to a comprehensive Web-based resource describing the genomic “fingerprints” of specific cancer types. Participants in this session will get an up-to-date progress report of TCGA.

*Chairs:* *Piotr Grodzinski, Henry Rodriguez, Daniela Gerhard, National Cancer Institute*

5:45 p.m. **Emerging Nanomedicine Opportunities in Cancer**

*Gregory Lanza, Washington University in St. Louis*

6:05 p.m. **Nanotechnology for Personalized and Predictive Oncology: Linking CCNE and SPORE**

*Shuming Nie, Emory University and Georgia Institute of Technology*

6:25 p.m. **The Cancer Genome Atlas: An Update**

*Daniela Gerhard, National Cancer Institute*

6:45 p.m. **Open Data and Informatics Resources for Investigating the Mouse Model Cancer Serum Proteome and Other Complex Biological Samples**

*Martin McIntosh, Fred Hutchinson Cancer Research Center*

7:05 p.m. **Discussion and Q&A**

---

**NIH Roadmap Initiative****Salon VI**

The NIH Roadmap represents a set of initiatives that the NIH and its stakeholders identified as the most compelling and important in order to bridge gaps and meet the needs of existing and emerging areas of science. This incubator space of opportunities covers three main themes: New Pathways to Discovery (building infrastructure, technology, and supporting emerging research areas), Research Teams of the Future (supporting collaborative team research and individual high-risk innovation), and Re-engineering the Clinical Research Enterprise (supporting the transformation of clinical research to accelerate the translation of discoveries from bench to bedside and back). This session will provide an overview of the set of NIH Roadmap Initiatives as well as inform SPORE investigators of ongoing and upcoming funding opportunities and initiatives related to cancer research. Additionally, funded investigators will share their experiences as part of the NIH Roadmap.

*Chairs: Lisa Colpe, Penny Burgoon, National Institutes of Health*

5:45 p.m. **Introduction: What Is the NIH Roadmap Initiative?**  
*Penny Burgoon, National Institutes of Health*

**5:55 p.m. NIH Roadmap Projects: Concepts and Goals, Research Opportunities, and Possibilities for Collaborations With Funded Research Initiatives**

5:55 p.m. **New Pathways to Discovery: Molecular Libraries and Imaging**  
*Daniel Zaharevitz, National Institutes of Health*

6:15 p.m. **New Pathways to Discovery: Bioinformatics and Computational Biology**  
*Daniel Zaharevitz, National Institutes of Health*

6:35 p.m. **New Pathways to Discovery: Structural Biology**  
*John Knowlton, National Institutes of Health*

6:55 p.m. **Clinical Research: Clinical Translational Sciences Awards**  
*Anthony Hayward, National Institutes of Health*

7:15 p.m. **Discussion**

---

## Poster Take-down

---

6:00 p.m.

Harborside Ballroom

---

## Satellite Meetings

---

7:45 p.m. - 9:45 p.m.

Prostate SPOREs Clinical  
Trials Working Group

Boardroom

Barrett's Esophagus and  
Esophageal Adenocarcinoma

Kent B

I-SPY Trial: Investigators' Meeting

Laurel A & B

---



**Internet Room**

7:00 a.m. - 12 noon Atlantic

**Speaker Ready Room**

7:00 a.m. - 12 noon Bristol

**Registration**

7:00 a.m. - 12 noon Grand Registration Desk

**Early Morning Break**

7:00 a.m. - 8:00 a.m. Various Locations

**Concurrent Plenary Sessions**

8:00 a.m. - 10:00 a.m.

At these sessions, each SPORE has the opportunity to highlight its most groundbreaking translational research, whether initially discovered from the laboratory proceeding to the clinic or a clinical observation being further investigated in a laboratory setting. These presentations reflect the best efforts of each SPORE to achieve a human application or intervention.

**Development of Biotechnologies in Cancer Research Salons I-IV**

*Chairs: Lawrence True, University of Washington  
Sarah Nelson, University of California, San Francisco*

8:00 a.m. **Genetic Data From Archival Tissue**  
*William Dupont, Vanderbilt University*

8:15 a.m. **Comparison of Four Scales for Quantifying Antigen Expression Immunoperoxidase Stains: Assessment of Agreement**  
*Lawrence True, University of Washington*

8:30 a.m. **Proteomic Analysis of Lung Cancer Tumors**  
*Takefumi Kikuchi, Vanderbilt University*

- 8:45 a.m. **A Highly Conserved and Broadly Neutralizing Epitope of L2 Critical to Human Papillomavirus Infection**  
*Richard Roden, Johns Hopkins University*
- 9:00 a.m. **Development of a CA125-Mesothelin Cell Adhesion as a Screening Tool for Biologics Discovery**  
*Nathalie Scholler, Fred Hutchinson Cancer Research Center*
- 9:15 a.m. **Molecular Cloning of the Human Lymphocyte Antigen (HLA) Class II-Dependent L8 Melanoma-Associated Antigen (Ag) Using Ag Phage Display**  
*Dorothee Herlyn, The Wistar Institute*
- 9:30 a.m. **Metabolomic Biomarkers of Non-Small Cell Lung Cancer**  
*William Bigbee, University of Pennsylvania*
- 9:45 a.m. **Development of a Molecular Imaging Program in Ovarian Cancer**  
*Richard Penson, Brigham and Women's Hospital*
- 10:00 a.m. **Ligand-Directed Molecular Imaging in Prostate Cancer: Implications for Diagnosis and Therapy**  
*Wadih Arap, University of Texas M.D. Anderson Cancer Center*
- 10:15 a.m. **Real-Time Convection-Enhanced Delivery of Therapeutic Liposomes to Canine Brain Tumors**  
*Mitchel Berger, University of California, San Francisco*
- 10:30 a.m. **The Isopeptidase USP2a Protects Human Prostate Cancer From Apoptosis**  
*Carmen Priolo, Dana-Farber/Harvard Cancer Center*
-

**Molecular Monitoring of Risk  
and Recurrence****Salon V**

*Chairs: William Nelson, Johns Hopkins University  
Janet Stanford, Fred Hutchinson Cancer  
Research Center*

- 8:00 a.m. **Environmental Tobacco Smoke (Secondhand Smoke) Is a Risk Factor for and Contributes to Younger Age of Onset of Pancreatic Cancer**  
*Gloria Petersen, Mayo Clinic, Rochester*
- 8:15 a.m. **LIG1 Haplotypes and Lung Cancer Risk**  
*Zuo-Feng Zhang, University of California, Los Angeles*
- 8:30 a.m. **Polymorphisms of the DNA Repair Gene XPC and Risk of Squamous Cell Carcinoma of the Head and Neck: A Case-Control Study**  
*Qingyi Wei, University of Texas M.D. Anderson Cancer Center*
- 8:45 a.m. **KLF4 Signals Through Notch in Epithelial Transformation and Tumorigenesis**  
*J. Michael Ruppert, University of Alabama at Birmingham*
- 9:00 a.m. **HOXB7 as a Master Regulator of Multiple Growth Factor Pathways Involved in the Development of Tamoxifen Resistance**  
*Saraswati Sukumar, Johns Hopkins University*
- 9:15 a.m. **HER4 and Breast Cancer Prognosis**  
*Shelton Earp, III, University of North Carolina at Chapel Hill*
- 9:30 a.m. **Cytochrome P450 2D6 Status Predicts Clinical Outcome in Women Receiving Adjuvant Tamoxifen**  
*Matthew Goetz, Mayo Clinic, Rochester*

- 9:45 a.m. **Genetic Variations in Platinum Action Pathways Modulate Therapeutic Response in Non-Small Cell Lung Cancer**  
*Xifeng Wu, University of Texas  
M.D. Anderson Cancer Center*
- 10:00 a.m. **Reactive Stroma in Prostate Cancer Progression**  
*Gustavo Ayala, Baylor College of Medicine*
- 10:15 a.m. **Molecular Metastasis to N2 Nodes May Predict Recurrence in Stage 1 Patients With Optimally Resected Non-Small Cell Lung Cancer**  
*Malcolm Brock, Johns Hopkins University*
- 10:30 a.m. **Cellular Epigenetic Heterogeneity in Primary Prostate Cancer Tissues Predicts Risk of Recurrence**  
*Siavash Kurdastani, University of California, Los Angeles*

**Development of Therapeutic Agents****Salon VI**

- Chairs: John Park, University of California, San Francisco  
John Isaacs, Johns Hopkins University*
- 8:00 a.m. **Chemoprevention of Ovarian Cancer in a Preclinical Model by Use of the mTOR Inhibitor RAD001**  
*Joseph Testa, Fox Chase Cancer Center*
- 8:15 a.m. **Curcumin and Emodin, Kinase Inhibitors of Jab1 Complex, Stabilize p27, p53, and Smad4 Expression and Sensitize Gemcitabine-Induced Apoptosis**  
*Mei Wan, University of Alabama at Birmingham*
- 8:30 a.m. **Immune Mediated Regression of Solid Mouse Prostate Cancer by Blockade of TGF- $\beta$  Signaling in Tumor-Reactive CD8+ T Cells in Immunodeficient Allogeneic Hosts**  
*Chung Lee, Northwestern University*

- 8:45 a.m. **Targeted Activation of Cytotoxic Prodrugs by Prostate-Specific Proteases**  
*Samuel Denmeade, Johns Hopkins University*
- 9:00 a.m. **Semaphorin SEMA3F Inhibits VEGF Transcription in Lung Cancer Cells**  
*Harry Drabkin, University of Colorado*
- 9:15 a.m. **Defining the Distinct Global Phosphotyrosine States of Normal and Src-Transformed Cells**  
*Steven Hanks, Vanderbilt University*
- 9:30 a.m. **Antitumor Activities of Perifosine, an Oral Bioactive Novel Alkylphospholipid, in Human Multiple Myeloma Cells**  
*Teru Hideshima, Dana-Farber/Harvard Cancer Center*
- 9:45 a.m. **Gene Reactivation for Enzymatically Targeted Radiotherapy**  
*Richard Ambinder, Johns Hopkins University*
- 10:00 a.m. **Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia**  
*William Bornmann, University of Texas M.D. Anderson Cancer Center*
- 10:15 a.m. **Primary B-Chronic Lymphocytic Leukemia Cells and Other B Cells Produce Functional Granzyme B in Response to IL-21-Based Immunotherapy**  
*George Weiner, University of Iowa*
-

**Human Therapeutic Interventions  
With Laboratory Correlates**
**Salons VII-X**

- Chairs:*      *Howard Scher, Memorial Sloan-Kettering  
Cancer Center*  
*Mace Rothenberg, Vanderbilt University*
- 8:00 a.m.      **Preliminary Translational Results of a  
Phase II Study of RAD001, an Oral  
mTOR Inhibitor, for Patients With  
Recurrent Endometrial Cancer**  
*Brian Slomovitz, University of Texas  
M.D. Anderson Cancer Center*
- 8:15 a.m.      **From Transformed Cells, Genetically  
Engineered Mice to Human Clinical  
Trials: The Experience With HKI-272, a  
Dual-Specific EGFR and ErbB2 Inhibitor,  
in Non-Small Cell Lung Cancer**  
*Kwok-Kin Wong, Dana-Farber/Harvard  
Cancer Center*
- 8:30 a.m.      **Intravesical Ad-IFN $\alpha$ /Syn3 for  
Superficial Bladder Cancer:  
Overcoming Resistance to the IFN  
Protein (Intron A)**  
*William Benedict, University of Texas  
M.D. Anderson Cancer Center*
- 8:45 a.m.      **Phase II Trial of Curcumin (Diferuloyl  
Methane), an NFB Inhibitor, in Patients  
With Advanced Pancreatic Cancer**  
*Razelle Kurzrock, University of Texas  
M.D. Anderson Cancer Center*
- 9:00 a.m.      **Early Clinical Development of a  
Thioredoxin-1 Inhibitor PX-12:  
Development of Pharmacodynamic  
Assays To Help Identify the Biologically  
Effective Dose**  
*Amanda Baker, University of Arizona*
- 9:15 a.m.      **Targeting Glioblastoma Signal  
Transduction**  
*Jeremy Rich, Duke University*
- 9:30 a.m.      **Development of  $\gamma\delta$  T Cells as Therapy  
for Glioblastoma Multiforme**  
*Lawrence Lamb, University of Alabama at  
Birmingham*

- 9:45 a.m. **Translating Ubiquitin Ligase-Dependent ErbB2 Down-Regulation Into Enhanced Response to Trastuzumab**  
*Hamid Band, Northwestern University*
- 10:00 a.m. **Complete Blockade of the HER Signaling Pathway Combined with ER-Targeted Therapy Eradicates Breast Tumors in a Xenograft Model**  
*Kent Osborne, Baylor College of Medicine*
- 10:15 a.m. **Novel Lipidic Nanoparticles and Immunoliposomes for Cancer Treatment**  
*John Park, University of California, San Francisco*

## Bladder SPORE Breakout Session II

**10:00 a.m. - 12 noon**

**Essex A-C**

- 10:00 a.m. **International Bladder Cancer Meeting, January 18-19, 2007**  
*Colin Dinney, University of Texas M.D. Anderson Cancer Center*

## Brain SPOREs Breakout Session II

**10:00 a.m. - 12 noon**

**Laurel C & D**

## Breast SPOREs Breakout Session II

**10:00 a.m. - 12 noon**

**Harborside B**

- Chairs:* *Joe Gray, University of California, San Francisco*  
*Shelton Earp, III, University of North Carolina at Chapel Hill*  
*Nancy Davidson, Johns Hopkins University*
- NIH* *Barbara Vonderhaar, Karen Johnson,*  
*Facilitators:* *Shamala Srinivas, National Cancer Institute*
- Opportunities for Breast SPORE Interactions With the Private Sector**  
*Moderator: Nancy Davidson, Johns Hopkins University*
- 10:00 a.m. *Mark Sliwkowski, Genentech*
- 10:30 a.m. *Mark Berger, GlaxoSmithKline*
- 11:00 a.m. *Robert Lipshutz, Affymetrix, Inc.*
- 11:30 a.m. **Discussion**

## Hematological Malignancies SPOREs Breakout Session II

10:00 a.m. - 12 noon

Laurel A & B

## Prostate SPOREs Breakout Session II

10:00 a.m. - 12 noon

Harborside A

*Chairs:* Kenneth Pienta, University of Michigan  
Christopher Logothetis, University of Texas  
M.D. Anderson Cancer Center  
Philip Kantoff, Dana-Farber Cancer Institute

*NIH* Alison Martin, William Figg, William Dahut,  
*Facilitators:* Suresh Mohla, National Cancer Institute

10:00 a.m. **CTLA-4 Blockade-Based  
Immunotherapy for Hormone-  
Refractory Prostate Cancer**  
*Eric Small, University of California,  
San Francisco*

10:15 a.m. **The Effect of BAY 43-9006 (Sorafenib)  
on Bone Lesions in Patients With  
Metastatic Androgen-Independent  
Prostate Cancer**  
*William Dahut, National Cancer Institute*

10:30 a.m. **A Randomized Phase II Study of  
Concurrent Docetaxel Plus Vaccine  
Versus Vaccine Alone in Metastatic  
Androgen-Independent Prostate Cancer**  
*Philip Arlen, National Cancer Institute*

10:45 a.m. **Inhibiting the Androgen Receptor and  
Androgen-Stimulated Gene Expression  
With Histone Deacetylase Inhibitors**  
*Howard Scher, Memorial Sloan-Kettering  
Cancer Center*

11:00 a.m. **IPBS Update**  
*Bruce Trock, Johns Hopkins University*

11:30 a.m. **NBN Network**  
*Mark Rubin, Dana-Farber Cancer Institute*



---

**Lung Pathologists' Meeting**

---

10:00 a.m. - 12 noon

Dover A & B

---

**Workshop Adjournment**

---

12 noon

---

**Advocate Wrap-up Session**

---

12 noon - 2:00 p.m.

James

---

Wednesday, July 19

## Planning Committee

James Abbruzzese, M.D., Director, Pancreatic SPORE  
University of Texas M.D. Anderson Cancer Center

Kenneth Anderson, M.D., Director, Myeloma SPORE  
Dana-Farber/Harvard Cancer Center

Robert Bast, Jr., M.D., Director, Ovarian SPORE  
University of Texas M.D. Anderson Cancer Center

Thomas Burke, M.D., Director, Gynecologic SPORE  
University of Texas M.D. Anderson Cancer Center

Gary Clayman, M.D., Director, Head and Neck SPORE  
University of Texas M.D. Anderson Cancer Center

Deborah Collyar, Co-Leader  
Patient Advocate Research Team Program

Colin Dinney, M.D., Director, Genitourinary SPORE  
University of Texas M.D. Anderson Cancer Center

Shelton Earp, III, M.D., Director, Breast SPORE  
University of North Carolina at Chapel Hill

Joe Gray, Ph.D., Director, Breast SPORE  
University of California, San Francisco

Meenhard Herlyn, D.V.M., Sc.D., Director, Skin SPORE  
The Wistar Institute/University of Pennsylvania

Jean-Pierre Issa, M.D., Director, Leukemia SPORE  
University of Texas M.D. Anderson Cancer Center

Scott Kern, M.D., Director, Gastrointestinal SPORE  
Johns Hopkins University

Paula Kim, Patient Advocate, Pancreatic SPORE  
University of Texas M.D. Anderson Cancer Center

Paul Lange, M.D., Director, Prostate SPORE  
University of Washington

Marston Linehan, M.D., Chief, Urologic Oncology Branch  
Center for Cancer Research, National Cancer Institute

Christopher Logothetis, M.D., Director, Prostate SPORE  
University of Texas M.D. Anderson Cancer Center

Brian O'Neill, M.D., Director, Brain SPORE  
Mayo Clinic, Rochester

Jill Siegfried, Ph.D., Director, Lung SPORE  
University of Pittsburgh

Patricia Steeg, Ph.D., Director, Molecular Therapeutics Program  
Center for Cancer Research, National Cancer Institute

David Sturges, Patient Advocate, Lung SPORE  
University of California, Los Angeles

George Weiner, M.D., Director, Lymphoma SPORE  
University of Iowa/Mayo Clinic, Rochester

## National Institutes of Health Facilitators

Michael Birrer, M.D., Ph.D.

William Dahut, M.D.

Geraldina Dominguez, Ph.D.

William Figg, Pharm.D.

Jane Fountain, Ph.D.

James Jacobson, Ph.D.

Libin Jia, Ph.D.

Karen Johnson, M.D., Ph.D., M.P.H.

Gary Kelloff, M.D.

Marston Linehan, M.D.

Tracy Lively, Ph.D.

Alison Martin, M.D.

Suresh Mohla, Ph.D.

Scott Saxman, M.D.

Yasaman Shirazi, Ph.D.

Shamala Srinivas, Ph.D.

Magdalena Thurin, Ph.D.

Ted Trimble, M.D.

Mukesh Verma, Ph.D.

Barbara Vonderhaar, Ph.D.

Paul Wagner, Ph.D.

Linda Weiss, Ph.D.

Brian Wojcik, Ph.D.

## Organ Systems Branch

Jorge Gomez, M.D., Ph.D., Chief

Teri Brown, Program Coordinator

Sarah Fabian, Program Coordinator

Katherine Sachs, Program Coordinator

Ivan Ding, M.D., Program Director

Andrew Hruszkewycz, M.D., Ph.D., Program Director

Peter Ujhazy, M.D., Ph.D., Program Director

**SPORE Directors**

James Abbruzzese, M.D., Pancreatic SPORE  
University of Texas M.D. Anderson Cancer Center

Richard Ambinder, M.D., Ph.D., Lymphoma SPORE  
Johns Hopkins University

Kenneth Anderson, M.D., Myeloma SPORE  
Dana-Farber/Harvard Cancer Center

Carlos Arteaga, M.D., Breast SPORE  
Vanderbilt University

Michael Atkins, M.D., Genitourinary SPORE  
Dana-Farber/Harvard Cancer Center

Robert Bast, M.D., Ovarian SPORE  
University of Texas M.D. Anderson Cancer Center

Stephen Baylin, M.D., Lung SPORE  
Johns Hopkins University

Mitchel Berger, M.D., Brain SPORE  
University of California, San Francisco

Darell Bigner, M.D., Ph.D., Brain SPORE  
Duke University

Kirby Bland, M.D., Breast SPORE  
Northwestern University

Paul Bunn, M.D., Lung SPORE  
University of Colorado Cancer Center

Thomas Burke, M.D., Gynecologic SPORE  
University of Texas M.D. Anderson Cancer Center

David Carbone, M.D., Ph.D., Lung SPORE  
Vanderbilt University

Gary Clayman, M.D., Head and Neck SPORE  
University of Texas M.D. Anderson Cancer Center

Robert Coffey, Jr., M.D., Gastrointestinal SPORE  
Vanderbilt University

Daniel Cramer, M.D., Ovarian SPORE  
Brigham and Women's Hospital

Nancy Davidson, M.D., Breast SPORE  
Johns Hopkins University

Jean deKernion, M.D., Prostate SPORE  
University of California, Los Angeles

Colin Dinney, M.D., Genitourinary SPORE  
University of Texas M.D. Anderson Cancer Center

Steven Dubinett, M.D., Lung SPORE  
University of California, Los Angeles

Shelton Earp, III, M.D., Breast SPORE  
University of North Carolina at Chapel Hill

Stephen Forman, M.D., Lymphoma SPORE  
Beckman Research Institute at City of Hope

Joe Gray, Ph.D., Breast SPORE  
University of California, San Francisco

Eugene Gerner, Ph.D., Gastrointestinal SPORE  
University of Arizona

G. Yancey Gillespie, Ph.D., Brain SPORE  
University of Alabama at Birmingham

Jennifer Grandis, M.D., Head and Neck SPORE  
University of Pittsburgh

Elizabeth Grimm, Ph.D., Skin SPORE  
University of Texas M.D. Anderson Cancer Center

Meenhard Herlyn, D.V.M., Sc.D., Skin SPORE  
The Wistar Institute/University of Pennsylvania

Gabriel Hortobagyi, M.D., FACP, Breast SPORE  
University of Texas M.D. Anderson Cancer Center

J. Dirk Iglehart, M.D., Breast SPORE  
Dana-Farber/Harvard Cancer Center

James Ingle, M.D., Breast SPORE  
Mayo Clinic, Rochester

Jean-Pierre Issa, M.D., Leukemia SPORE  
University of Texas M.D. Anderson Cancer Center

Bruce Johnson, M.D., Lung SPORE  
Dana-Farber/Harvard Cancer Center

Philip Kantoff, M.D., Prostate SPORE  
Dana-Farber/Harvard Cancer Center

Scott Kern, M.D., Gastrointestinal SPORE  
Johns Hopkins University

Thomas Kupper, M.D., Skin SPORE  
Brigham and Women's Hospital

Paul Lange, M.D., Prostate SPORE  
University of Washington/Fred Hutchinson Cancer Research Center

Chung Lee, Ph.D., Prostate SPORE  
Northwestern University

Christopher Logothetis, M.D., Prostate SPORE  
University of Texas M.D. Anderson Cancer Center

H. Kim Lyerly, M.D., Breast SPORE  
Duke University

John Minna, M.D., Lung SPORE  
University of Texas Southwestern Medical Center/  
M.D. Anderson Cancer Center

William Nelson, M.D., Ph.D., Prostate SPORE  
Johns Hopkins University

Brian O'Neill, M.D., Brain SPORE  
Mayo Clinic, Rochester

C. Kent Osborne, M.D., Breast SPORE  
Baylor College of Medicine

Robert Ozols, M.D., Ph.D., Ovarian SPORE  
Fox Chase Cancer Center

Gloria Petersen, Ph.D., Pancreatic SPORE  
Mayo Clinic, Rochester

Kenneth Pienta, M.D., Prostate SPORE  
University of Michigan

Peter Scardino, M.D., Prostate SPORE  
Memorial Sloan-Kettering Cancer Center

Marc Shuman, M.D., Prostate SPORE  
University of California, San Francisco

David Sidransky, M.D., Head and Neck SPORE  
Johns Hopkins University

Jill Siegfried, Ph.D., Lung SPORE  
University of Pittsburgh

Joel Tepper, M.D., Gastrointestinal SPORE  
University of North Carolina at Chapel Hill

Timothy Thompson, Ph.D., Prostate SPORE  
Baylor College of Medicine

Donald Tindall, Ph.D., Prostate SPORE  
Mayo Clinic, Rochester

Nicole Urban, Sc.D., Ovarian SPORE  
Fred Hutchinson Cancer Research Center


Selwyn Vickers, M.D., Pancreatic SPORE  
University of Alabama at Birmingham

George Weiner, M.D., Lymphoma SPORE  
University of Iowa/Mayo Clinic, Rochester


Gregory Wolf, M.D., Head and Neck SPORE  
University of Michigan

T.C. Wu, M.D., Ph.D., Gynecologic SPORE  
Johns Hopkins University


# Grand Ballroom



# Harborside Ballroom



# Waterview Ballroom



Entrance to the Waterview Ballroom is from a designated elevator in the Grand Ballroom Foyer. Please refer to the Grand Ballroom Level Floorplan.